Tofacitinib Lowers Risk Of Death Or Respiratory Failure In C
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Researchers have found in a new study that among patients hospitalized with Covid-19 pneumonia, tofacitinib led to a lower risk of death or respiratory failure through day 28 than placebo. In this trial involving hospitalized patients with Covid-19 pneumonia, tofacitinib was superior to placebo in reducing the incidence of death or respiratory failure through day 28.

These effects were consistent regardless of sex, age, duration of symptoms, and use of glucocorticoids at baseline; they were also consistent across different levels of supplemental oxygen use at baseline. The positive findings from the STOP-COVID study evaluating the efficacy and safety of oral Janus kinase (JAK) inhibitor tofacitinib was done in 289 hospitalized adult patients with COVID-19 pneumonia who were not on ventilation.

The trial demonstrated a lower cumulative incidence of death or respiratory failure through day 28 with tofacitinib (18.1%) compared to placebo (29.0%). Death from any cause through day 28 occurred in 2.8% of patients in the tofacitinib group and in 5.5% in the placebo group. Serious adverse events occurred in 20 patients (14.1%) in the tofacitinib group and 17 (12.0%) in the placebo group. The incidence of serious infection was 3.5% in the tofacitinib group and 4.2% in the placebo group.

"We are encouraged by the initial findings of our randomized trial of tofacitinib in patients hospitalized with COVID-19 pneumonia. These results provide new information which indicates that the use of tofacitinib when added to standard of care, which includes glucocorticoids, may further reduce the risk of death or respiratory failure in this patient population," said Otavio Berwanger, M.D., Ph.D., Director of the Academic Research Organization, Hospital Israelita Albert Einstein.

The multi-center, randomized, double-blind, placebo-controlled trial included adult patients hospitalized with COVID-19 pneumonia receiving standard of care. Patients were randomized in a 1:1 ratio to receive either tofacitinib 10 mg twice daily plus standard of care or placebo twice daily plus standard of care for up to 14 days or until hospital discharge. Overall, 89.3% used glucocorticoids during hospitalization, predominantly dexamethasone.

Source:
https://www.nejm.org/doi/full/10.1056/NEJMoa2101643
1 share
Like
Comment
Share